DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Tolerability of Buprenorphine/Naloxone Film Strips

Information source: Reckitt Benckiser Pharmaceuticals Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Opioid-Related Disorders

Intervention: Buprenorphine/naloxone Film Strip (Drug); Buprenorphine/naloxone Film Strip (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Reckitt Benckiser Pharmaceuticals Inc.

Official(s) and/or principal investigator(s):
Donald R. Jasinski, MD, Principal Investigator, Affiliation: Johns Hopkins University

Summary

This study will evaluate the safety and tolerability on the oral mucosa of buprenorphine/naloxone film strips administered either sublingually or buccally daily for 12 weeks in opioid dependent individuals who are already on a stable regimen of buprenorphine/naloxone.

Clinical Details

Official title: A Phase 2 Multi-Center Open-label Study to Assess the Safety and Tolerability of a Buprenorphine/Naloxone Film Strip Administered by the Sublingual and Buccal Routes

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity.

Number of Subjects With Mild, Moderate or Severe Treatment-emergent Adverse Events Associated With the Oral Cavity

Detailed description: Buprenorphine and naloxone soluble film was developed as an alternative dosage form to Suboxone (buprenorphine and naloxone) sublingual tablets and was evaluated for both sublingual and buccal administration. The soluble film dosage is expected to provide the following enhancements and potential advantages over the current Suboxone (buprenorphine and naloxone) product:

- mitigation against unintentional pediatric exposure by providing child-resistant

packaging in unit dose format.

- improvement in subject convenience and compliance by ensuring rapid disintegration.

- protection against diversion by providing a dosage form that is very difficult for the

subject to remove from the sublingual or buccal mucosa after administration. This provides assurance to the caregiver that the dose has actually been taken appropriately in a supervised setting.

- provision of a unit dose product format for hospital and institutional use.

- decreased product damage during shipping as compared to Suboxone tablets.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Subjects must:

- Be 18-to-65 years of age, inclusive.

- Have a diagnosis of opioid dependence by medical history according to DSM-IV-TR

criteria.

- Be on stable dose of 4 to 32 mg (expressed as the buprenorphine component)daily of

Suboxone for at least 30 days.

- If female, have a negative pregnancy test during screening and agree to use an

acceptable method of birth control which may include: Exclusion Criteria: Subjects must not:

- Have participated in an experimental drug or device study within the last 30 days.

- If female, be breast feeding or lactating.

- Have any medical condition that in the opinion of the physician investigator would

preclude the subject from completing the study.

- Have a clinically significant abnormal finding (in the opinion of the Investigator)

on oral cavity exam (e. g., active mouth ulcers).

- Have any piercing of the tongue or mouth within 30 days prior to the first dose of

study medication.

Locations and Contacts

Parkway Medical Center, Birmingham, Alabama 35215, United States

Winston Technology Research LLC, Haleyville, Alabama 35565, United States

Beeches Family Medicine, Jacksonville Beach, Florida 32250, United States

Additional Information

Starting date: February 2008
Last updated: November 6, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017